AI assistant
Tourmaline Bio, Inc. — Director's Dealing 2021
May 7, 2021
32658_dirs_2021-05-06_aaea1c87-e141-4d3d-b109-74a03c2518bc.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Talaris Therapeutics, Inc. (TALS)
CIK: 0001827506
Period of Report: 2021-05-06
Reporting Person: MACKAY GEOFFREY (Director)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $0.90 | 2028-12-20 | Common Stock (31542) | Direct | |
| Stock Option (Right to Buy) | $0.96 | 2030-02-07 | Common Stock (18691) | Direct | |
| Stock Option (Right to Buy) | $3.90 | 2030-08-20 | Common Stock (6633) | Direct | |
| Stock Option (Right to Buy) | $5.72 | 2030-10-02 | Common Stock (19922) | Direct |
Footnotes
F1: The shares underlying this option shall vest as follows: 25% vested on November 16, 2019; and the remaining shall vest in 36 equal monthly installments thereafter.
F2: The shares underlying this option shall vest in 48 equal monthly installments beginning on the vesting commencement date of December 5, 2019.
F3: The shares underlying this option shall vest in 48 equal monthly installments beginning on the vesting commencement date of August 20, 2020
F4: The shares underlying this option shall vest in 48 equal monthly installments beginning on the vesting commencement date of October 2, 2020.